Chinese drugmaker BeiGene shares soar on US market
By Wu Yiyao in Shanghai | China Daily | Updated: 2018-01-05 07:29
The share price of Nasdaq-listed Chinese biopharmaceutical company BeiGene more than tripled in 2017 even though its products have not yet been put on the market, indicating investors' strong interest in the company's offerings.
Even though it's rare for a company's share price to skyrocket when its products are yet to be offered, a report from the Motley Fool, a US investment analytics website, indicates there is still more potential for the stock to grow, supported by BeiGene's fundamentals.
BeiGene is a commercial-stage, research-based biopharmaceutical company focused on molecularly targeted and immune-oncology cancer therapeutics. Its share price rose from some $30 to more than $96 in 2017, with capitalization of about $4.4 billion.
Photo